Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1105

1.

A model of overall survival predicts treatment outcomes with atezolizumab vs chemotherapy in non-small cell lung cancer based on early tumor kinetics.

Claret L, Jin JY, Ferté C, Winter H, Girish S, Stroh M, He P, Ballinger M, Sandler A, Joshi A, Rittmeyer A, Gandara DR, Soria JC, Bruno R.

Clin Cancer Res. 2018 Apr 23. pii: clincanres.3662.2017. doi: 10.1158/1078-0432.CCR-17-3662. [Epub ahead of print]

PMID:
29685883
2.

Monotypic low-level HIV viremias during ART are associated with disproportionate production of X4 virions and systemic immune activation.

Bull ME, Mitchell C, Soria J, Styrchak S, Williams-Wietzikoski C, Legard J, Mckernan-Mullin J, Kraft K, Onchiri F, Stern J, Holte S, Ryan KJ, Acosta EP, La Rosa A, Coombs RW, Ticona E, Frenkel LM.

AIDS. 2018 Apr 19. doi: 10.1097/QAD.0000000000001824. [Epub ahead of print]

PMID:
29683841
3.

Temperature Effects Explain Continental Scale Distribution of Cyanobacterial Toxins.

Mantzouki E, Lürling M, Fastner J, de Senerpont Domis L, Wilk-Woźniak E, Koreivienė J, Seelen L, Teurlincx S, Verstijnen Y, Krztoń W, Walusiak E, Karosienė J, Kasperovičienė J, Savadova K, Vitonytė I, Cillero-Castro C, Budzyńska A, Goldyn R, Kozak A, Rosińska J, Szeląg-Wasielewska E, Domek P, Jakubowska-Krepska N, Kwasizur K, Messyasz B, Pełechaty A, Pełechaty M, Kokocinski M, García-Murcia A, Real M, Romans E, Noguero-Ribes J, Duque DP, Fernández-Morán E, Karakaya N, Häggqvist K, Demir N, Beklioğlu M, Filiz N, Levi EE, Iskin U, Bezirci G, Tavşanoğlu ÜN, Özhan K, Gkelis S, Panou M, Fakioglu Ö, Avagianos C, Kaloudis T, Çelik K, Yilmaz M, Marcé R, Catalán N, Bravo AG, Buck M, Colom-Montero W, Mustonen K, Pierson D, Yang Y, Raposeiro PM, Gonçalves V, Antoniou MG, Tsiarta N, McCarthy V, Perello VC, Feldmann T, Laas A, Panksep K, Tuvikene L, Gagala I, Mankiewicz-Boczek J, Yağcı MA, Çınar Ş, Çapkın K, Yağcı A, Cesur M, Bilgin F, Bulut C, Uysal R, Obertegger U, Boscaini A, Flaim G, Salmaso N, Cerasino L, Richardson J, Visser PM, Verspagen JMH, Karan T, Soylu EN, Maraşlıoğlu F, Napiórkowska-Krzebietke A, Ochocka A, Pasztaleniec A, Antão-Geraldes AM, Vasconcelos V, Morais J, Vale M, Köker L, Akçaalan R, Albay M, Špoljarić Maronić D, Stević F, Žuna Pfeiffer T, Fonvielle J, Straile D, Rothhaupt KO, Hansson LA, Urrutia-Cordero P, Bláha L, Geriš R, Fránková M, Koçer MAT, Alp MT, Remec-Rekar S, Elersek T, Triantis T, Zervou SK, Hiskia A, Haande S, Skjelbred B, Madrecka B, Nemova H, Drastichova I, Chomova L, Edwards C, Sevindik TO, Tunca H, Önem B, Aleksovski B, Krstić S, Vucelić IB, Nawrocka L, Salmi P, Machado-Vieira D, de Oliveira AG, Delgado-Martín J, García D, Cereijo JL, Gomà J, Trapote MC, Vegas-Vilarrúbia T, Obrador B, Grabowska M, Karpowicz M, Chmura D, Úbeda B, Gálvez JÁ, Özen A, Christoffersen KS, Warming TP, Kobos J, Mazur-Marzec H, Pérez-Martínez C, Ramos-Rodríguez E, Arvola L, Alcaraz-Párraga P, Toporowska M, Pawlik-Skowronska B, Niedźwiecki M, Pęczuła W, Leira M, Hernández A, Moreno-Ostos E, Blanco JM, Rodríguez V, Montes-Pérez JJ, Palomino RL, Rodríguez-Pérez E, Carballeira R, Camacho A, Picazo A, Rochera C, Santamans AC, Ferriol C, Romo S, Soria JM, Dunalska J, Sieńska J, Szymański D, Kruk M, Kostrzewska-Szlakowska I, Jasser I, Žutinić P, Gligora Udovič M, Plenković-Moraj A, Frąk M, Bańkowska-Sobczak A, Wasilewicz M, Özkan K, Maliaka V, Kangro K, Grossart HP, Paerl HW, Carey CC, Ibelings BW.

Toxins (Basel). 2018 Apr 13;10(4). pii: E156. doi: 10.3390/toxins10040156.

4.

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.

Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V.

Lancet Oncol. 2018 Apr 9. pii: S1470-2045(18)30145-1. doi: 10.1016/S1470-2045(18)30145-1. [Epub ahead of print]

PMID:
29650362
5.

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.

Herin H, Aspeslagh S, Castanon E, Dyevre V, Marabelle A, Varga A, Postel Vinay S, Michot JM, Ribrag V, Gazzah A, Bahleda R, Mir O, Massard C, Hollebecque A, Soria JC, Baldini C.

Eur J Cancer. 2018 Apr 7;95:68-74. doi: 10.1016/j.ejca.2018.03.002. [Epub ahead of print]

PMID:
29635146
6.

Osimertinib in EGFR Mutation-Positive Advanced NSCLC.

Soria JC, Ramalingam SS.

N Engl J Med. 2018 Mar 29;378(13):1262-1263. doi: 10.1056/NEJMc1801669. No abstract available.

7.

Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer.

Muñoz Martín AJ, Ortega I, Font C, Pachón V, Castellón V, Martínez-Marín V, Salgado M, Martínez E, Calzas J, Rupérez A, Souto JC, Martín M, Salas E, Soria JM.

Br J Cancer. 2018 Apr;118(8):1056-1061. doi: 10.1038/s41416-018-0027-8. Epub 2018 Mar 28.

PMID:
29588512
8.

Immuno-Oncology in Cancer Care is a Fantastic Opportunity for Interventional Oncology: IO4IO (Interventional Oncology for Immuno-Oncology) Initiative.

de Baère T, Tselikas L, Deschamps F, Soria JC, Marabelle A.

Cardiovasc Intervent Radiol. 2018 Mar 16. doi: 10.1007/s00270-018-1935-y. [Epub ahead of print] No abstract available.

PMID:
29549416
9.

Does smoking alter the mutation profile of human papillomavirus-driven head and neck cancers?

Mirghani H, Lacroix L, Rossoni C, Sun R, Aupérin A, Casiraghi O, Villepelet A, Lacave R, Faucher G, Marty V, Ferté C, Soria JC, Even C.

Eur J Cancer. 2018 May;94:61-69. doi: 10.1016/j.ejca.2018.02.013. Epub 2018 Mar 20.

PMID:
29533868
10.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

Cabel L, Fuerea A, Lacroix L, Baldini C, Martin P, Hollebecque A, Postel-Vinay S, Varga A, Balheda R, Gazzah A, Michot JM, Marabelle A, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, Scoazec JY, Ammari S, André F, Soria JC, Massard C, Verlingue L.

Oncotarget. 2018 Jan 12;9(11):9741-9750. doi: 10.18632/oncotarget.24188. eCollection 2018 Feb 9.

11.

lme4qtl: linear mixed models with flexible covariance structure for genetic studies of related individuals.

Ziyatdinov A, Vázquez-Santiago M, Brunel H, Martinez-Perez A, Aschard H, Soria JM.

BMC Bioinformatics. 2018 Feb 27;19(1):68. doi: 10.1186/s12859-018-2057-x.

12.

A novel antibody-based approach to detect the functional ERCC1-202 isoform.

Kuo MS, Adam J, Dorvault N, Robin A, Friboulet L, Soria JC, Olaussen KA.

DNA Repair (Amst). 2018 Apr;64:34-44. doi: 10.1016/j.dnarep.2018.02.002. Epub 2018 Feb 11.

PMID:
29482102
13.

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.

Ricordel C, Friboulet L, Facchinetti F, Soria JC.

Ann Oncol. 2018 Jan 1;29(suppl_1):i28-i37. doi: 10.1093/annonc/mdx705.

PMID:
29462256
14.

Corrigendum to "Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial" [Eur J Cancer 87 (2017) 122-130].

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A.

Eur J Cancer. 2018 Apr;93:156-157. doi: 10.1016/j.ejca.2018.01.077. Epub 2018 Feb 14. No abstract available.

PMID:
29454743
15.

DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade.

Touat M, Sourisseau T, Dorvault N, Chabanon RM, Garrido M, Morel D, Krastev DB, Bigot L, Adam J, Frankum JR, Durand S, Pontoizeau C, Souquère S, Kuo MS, Sauvaigo S, Mardakheh F, Sarasin A, Olaussen KA, Friboulet L, Bouillaud F, Pierron G, Ashworth A, Lombès A, Lord CJ, Soria JC, Postel-Vinay S.

J Clin Invest. 2018 Apr 2;128(4):1671-1687. doi: 10.1172/JCI90277. Epub 2018 Mar 19.

16.

Epigenetic modifiers as new immunomodulatory therapies in solid tumours.

Aspeslagh S, Morel D, Soria JC, Postel-Vinay S.

Ann Oncol. 2018 Apr 1;29(4):812-824. doi: 10.1093/annonc/mdy050.

PMID:
29432557
17.

Multilayer global longitudinal strain in patients with cancer: A comparison of two vendors.

Ancedy Y, Ederhy S, Lang S, Hollebecque A, Dufour LS, Adavane-Scheuble S, Etienney A, Chauvet M, Soria JC, Cohen A.

Arch Cardiovasc Dis. 2018 Feb 5. pii: S1875-2136(18)30001-9. doi: 10.1016/j.acvd.2017.11.003. [Epub ahead of print]

PMID:
29422386
18.

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.

Sun JX, He Y, Sanford E, Montesion M, Frampton GM, Vignot S, Soria JC, Ross JS, Miller VA, Stephens PJ, Lipson D, Yelensky R.

PLoS Comput Biol. 2018 Feb 7;14(2):e1005965. doi: 10.1371/journal.pcbi.1005965. eCollection 2018 Feb.

19.

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot JM, Marabelle A, Mir O, Arnedos M, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, André F, Deutsch E, Scoazec JY, Soria JC, Massard C.

Eur J Cancer. 2018 Mar;92:1-10. doi: 10.1016/j.ejca.2017.12.020. Epub 2018 Feb 3.

PMID:
29413684
20.

Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE.

Gaspar N, Marshall LV, Binner D, Herold R, Rousseau R, Blanc P, Capdeville R, Carleer J, Copland C, Kerloeguen Y, Norga K, Pacaud L, Sevaux MA, Spadoni C, Sterba J, Ligas F, Taube T, Uttenreuther-Fischer M, Chioato S, O'Connell MA, Geoerger B, Blay JY, Soria JC, Kaye S, Wulff B, Brugières L, Vassal G, Pearson ADJ; Members of Working Group 1 of the Paediatric Platform of ACCELERATE.

Ann Oncol. 2018 Mar 1;29(3):766-771. doi: 10.1093/annonc/mdy002. No abstract available.

21.

TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma.

Leduc C, Adam J, Louvet E, Sourisseau T, Dorvault N, Bernard M, Maingot E, Faivre L, Cassin-Kuo MS, Boissier E, Dessoliers MC, Robin A, Casiraghi O, Even C, Temam S, Olaussen KA, Soria JC, Postel-Vinay S.

ESMO Open. 2018 Jan 9;3(1):e000257. doi: 10.1136/esmoopen-2017-000257. eCollection 2018.

22.

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.

Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, Powles T, Smith D, Hoos A, McKenna C, Beyer U, Rhee I, Fine G, Winslow N, Chen DS, Wolchok JD.

J Clin Oncol. 2018 Mar 20;36(9):850-858. doi: 10.1200/JCO.2017.75.1644. Epub 2018 Jan 17.

PMID:
29341833
23.

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.

Bahleda R, Varga A, Bergé Y, Soria JC, Schnell D, Tschoepe I, Uttenreuther-Fischer M, Delord JP.

Br J Cancer. 2018 Feb 6;118(3):344-352. doi: 10.1038/bjc.2017.436. Epub 2018 Jan 16.

PMID:
29337963
24.

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O.

Eur J Cancer. 2018 Mar;91:21-29. doi: 10.1016/j.ejca.2017.12.008. Epub 2018 Jan 10.

PMID:
29331748
25.

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B.

JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771.

PMID:
29327044
26.

Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3.

Buart S, Terry S, Noman MZ, Lanoy E, Boutros C, Fogel P, Dessen P, Meurice G, Gaston-Mathé Y, Vielh P, Roy S, Routier E, Marty V, Ferlicot S, Legrès L, Bouchtaoui ME, Kamsu-Kom N, Muret J, Deutsch E, Eggermont A, Soria JC, Robert C, Chouaib S.

Oncotarget. 2017 Oct 30;8(65):108786-108801. doi: 10.18632/oncotarget.22150. eCollection 2017 Dec 12.

27.

[Hodgkin lymphoma: Current and future therapeutic strategies].

Turpin A, Michot JM, Kempf E, Mazeron R, Dartigues P, Terroir M, Boros A, Bonnetier S, Castilla-Llorente C, Coman T, Danu A, Ghez D, Pilorge S, Arfi-Rouche J, Dercle L, Soria JC, Carde P, Ribrag V, Fermé C, Lazarovici J.

Bull Cancer. 2018 Jan;105(1):81-98. doi: 10.1016/j.bulcan.2017.11.008. Epub 2017 Dec 27. Review. French.

PMID:
29289336
28.

Tear proteome analysis in ocular surface diseases using label-free LC-MS/MS and multiplexed-microarray biomarker validation.

Soria J, Acera A, Merayo-LLoves J, Durán JA, González N, Rodriguez S, Bistolas N, Schumacher S, Bier FF, Peter H, Stöcklein W, Suárez T.

Sci Rep. 2017 Dec 12;7(1):17478. doi: 10.1038/s41598-017-17536-2.

29.

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.

Krug AK, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A, Brinkmann K, Emenegger J, Grimm DG, Castellanos-Rizaldos E, Goldman JW, Sequist LV, Soria JC, Camidge DR, Gadgeel SM, Wakelee HA, Raponi M, Noerholm M, Skog J.

Ann Oncol. 2018 Mar 1;29(3):700-706. doi: 10.1093/annonc/mdx765.

30.

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer.

Blackhall F, Ross Camidge D, Shaw AT, Soria JC, Solomon BJ, Mok T, Hirsh V, Jänne PA, Shi Y, Yang PC, Pas T, Hida T, Carpeño JC, Lanzalone S, Polli A, Iyer S, Reisman A, Wilner KD, Kim DW.

ESMO Open. 2017 Aug 17;2(3):e000219. doi: 10.1136/esmoopen-2017-000219. eCollection 2017.

31.

LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.

Facchinetti F, Bluthgen MV, Tergemina-Clain G, Faivre L, Pignon JP, Planchard D, Remon J, Soria JC, Lacroix L, Besse B.

Lung Cancer. 2017 Oct;112:62-68. doi: 10.1016/j.lungcan.2017.08.002. Epub 2017 Aug 7.

PMID:
29191602
32.

Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.

Mezquita L, Charrier M, Faivre L, Dupraz L, Lueza B, Remon J, Planchard D, Bluthgen MV, Facchinetti F, Rahal A, Polo V, Gazzah A, Caramella C, Adam J, Pignon JP, Soria JC, Chaput N, Besse B.

Lung Cancer. 2017 Oct;112:10-15. doi: 10.1016/j.lungcan.2017.07.004. Epub 2017 Jul 29.

PMID:
29191581
33.

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.

Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, Balleyguier C, Planchard D, Gazzah A, Soria JC, Marabelle A, Besse B, Caramella C.

Eur J Cancer. 2018 Jan;88:38-47. doi: 10.1016/j.ejca.2017.10.017. Epub 2017 Nov 26.

PMID:
29182990
34.

[Infection by the Mycobacterium avium-intracellulare complex in patients with HIV/AIDS in a Peruvian hospital: A series of cases].

Ticona-Huaroto C, Astocondor-Salazar L, Montenegro-Idrogo J, Valencia-Mesias G, Soria J.

Rev Peru Med Exp Salud Publica. 2017 Apr-Jun;34(2):323-327. doi: 10.17843/rpmesp.2017.342.2476. Spanish.

35.

[High frequency of dyslipidemia in VIH-infected patients in aa peruvian public hospital].

Rondan PL, Flores-Flores O, Doria NA, Valencia-Mesias G, Chávez-Pérez V, Soria J.

Rev Peru Med Exp Salud Publica. 2017 Apr-Jun;34(2):239-244. doi: 10.17843/rpmesp.2017.342.2587. Spanish.

36.

[Results of conservative surgical management of ureteral injuries].

Soria J, Guandalino M, Vedrine N, Pereira B, Guy L.

Prog Urol. 2018 Feb;28(2):120-127. doi: 10.1016/j.purol.2017.10.011. Epub 2017 Nov 20. French.

PMID:
29162380
37.

Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.

Koeppel F, Blanchard S, Jovelet C, Genin B, Marcaillou C, Martin E, Rouleau E, Solary E, Soria JC, André F, Lacroix L.

PLoS One. 2017 Nov 21;12(11):e0188174. doi: 10.1371/journal.pone.0188174. eCollection 2017.

38.

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators.

N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.

PMID:
29151359
39.

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A.

Eur J Cancer. 2017 Dec;87:122-130. doi: 10.1016/j.ejca.2017.10.013. Epub 2017 Nov 14. Erratum in: Eur J Cancer. 2018 Feb 14;:.

PMID:
29145038
40.

The European Society for Medical Oncology (ESMO) Precision Medicine Glossary.

Yates LR, Seoane J, Le Tourneau C, Siu LL, Marais R, Michiels S, Soria JC, Campbell P, Normanno N, Scarpa A, Reis-Filho JS, Rodon J, Swanton C, Andre F.

Ann Oncol. 2018 Jan 1;29(1):30-35. doi: 10.1093/annonc/mdx707.

PMID:
29140430
41.

In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?

Aspeslagh S, Matias M, Palomar V, Dercle L, Lanoy E, Soria JC, Postel-Vinay S.

Eur J Cancer. 2017 Dec;87:65-74. doi: 10.1016/j.ejca.2017.09.027. Epub 2017 Nov 7.

PMID:
29126088
42.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
43.

Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.

Bahleda R, Le Deley MC, Bernard A, Chaturvedi S, Hanley M, Poterie A, Gazzah A, Varga A, Touat M, Deutsch E, Massard C, Van De Velde H, Hollebecque A, Sallansonnet-Froment M, Ricard D, Taillia H, Angevin E, Ribrag V, Soria JC.

Invest New Drugs. 2017 Nov 2. doi: 10.1007/s10637-017-0531-3. [Epub ahead of print]

PMID:
29094232
44.

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B.

J Clin Oncol. 2018 Jan 1;36(1):7-13. doi: 10.1200/JCO.2017.73.6785. Epub 2017 Oct 26.

45.

Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies.

Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, Loirat D, Buisson A, Rosa I, Lambotte O, Laghouati S, Chaput N, Coutzac C, Voisin AL, Soria JC, Marabelle A, Champiat S, Robert C, Carbonnel F.

Ann Oncol. 2017 Nov 1;28(11):2860-2865. doi: 10.1093/annonc/mdx403.

PMID:
29045560
46.

SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.

Soria JC, Fülöp A, Maciel C, Fischer JR, Girotto G, Lago S, Smit E, Ostoros G, Eberhardt WEE, Lishkovska P, Lovick S, Mariani G, McKeown A, Kilgour E, Smith P, Bowen K, Kohlmann A, Carlile DJ, Jänne PA.

Ann Oncol. 2017 Dec 1;28(12):3028-3036. doi: 10.1093/annonc/mdx628.

47.

Affected pathways and transcriptional regulators in gene expression response to an ultra-marathon trail: Global and independent activity approaches.

Maqueda M, Roca E, Brotons D, Soria JM, Perera A.

PLoS One. 2017 Oct 13;12(10):e0180322. doi: 10.1371/journal.pone.0180322. eCollection 2017.

48.

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.

Soria JC, Adjei AA, Bahleda R, Besse B, Ferte C, Planchard D, Zhou J, Ware J, Morrissey K, Shankar G, Lin W, Schutzman JL, Dy GK, Groen HJM.

Eur J Cancer. 2017 Nov;86:186-196. doi: 10.1016/j.ejca.2017.08.027. Epub 2017 Oct 6.

PMID:
28992562
49.

[New treatments in immuno-oncology: a revolution and a formidable scientific and clinical challenge].

Champiat S, Soria JC.

Med Sci (Paris). 2017 Jun-Jul;33(6-7):563-564. doi: 10.1051/medsci/20173306001. Epub 2017 Jul 19. French. No abstract available.

PMID:
28990546
50.

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC.

J Clin Oncol. 2017 Dec 20;35(36):4027-4034. doi: 10.1200/JCO.2017.73.9250. Epub 2017 Oct 2.

PMID:
28968167

Supplemental Content

Support Center